Cytotoxic constituents of propolis from Myanmar and their structure-activity relationship

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 12, 2009, Pages 2075-2078

  Li, Feng ^a   Awale, Suresh ^a   Tezuka, Yasuhiro ^a   Kadota, Shigetoshi ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Cycloartane type triterpene; Cytotoxicity; Flavanone; Propolis; Structure activity relationship

Indexed keywords

27 HYDROXYLMANGIFERONIC ACID; 28 HYDROXYMANGIFERONIC ACID; 3 ALPHA, 27 DIHYDROXYCYCLOART 24 EN 26 OIC ACID; 3 BETA, 22 DIHYDROXYCYCLOART 24 EN 26 OIC ACID; 3 BETA, 23 DIHYDROXYCYCLOART 24 EN 26 OIC ACID; 3 BETA, 27 DIHYDROXYCYCLOART 24 EN 26 OIC ACID; 3 OXO 23 HYDROXYCYCLOART 24 EN 26 OIC ACID; 3 OXO 27,28 DIHYDROXYCYCLOART 24 EN 26 OIC ACID; 3 OXO CYCLOART 22,24 DIEN 26 OIC ACID; 5,7 DIHYDROXY 4' METHOXY 8 PRENYLFLAVANONE; 5,7 DIHYDROXY 4' METHOXY 8,3' DIPRENYLFLAVANONE; 5,7,4' TRIHYDROXY 8 PRENYLFLAVANONE; 5,7,4' TRIHYDROXY 8,3' DIPRENYLFLAVANONE; DOXORUBICIN; FLAVANONE DERIVATIVE; FLUOROURACIL; MANGIFERIN; MANGIFEROLIC ACID; MANGIFERONIC ACID; PROPOLIS; TRIHEXYPHENIDYL; TRITERPENE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; FIBROSARCOMA; HELA CELL; HUMAN; HUMAN CELL; IC 50; LEWIS CARCINOMA; LUNG ADENOCARCINOMA; MELANOMA B16; MYANMAR; PRENYLATION; STRUCTURE ACTIVITY RELATION; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APITHERAPY; CELL LINE, TUMOR; FEMALE; FLAVANONES; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MYANMAR; NEOPLASMS; PRENYLATION; PROPOLIS; STRUCTURE-ACTIVITY RELATIONSHIP; TRITERPENES;

EID: 73449093853     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.2075     Document Type: Article

References (31)

1. Rocha G. G., Simões M., Lúcio K. A., Oliveira R. R., Coelho Kaplan M. A., Gattass C. R., Bioorg. Med. Chem., 15, 7355-7360 (2007).
2. Balachandran P., Govindarajan R., Pharmacol. Res., 51, 19-30 (2005).
3. Boyle P., Levin B., "World Cancer Report 2008," Section 1.1, World Health Organization, International Agency for Research on Cancer, Lyon, 2008, pp. 12-39.
4. Castaldo S., Capasso F., Fitoterapia, 73, S1-S6 (2002).
5. Banskota A. H., Tezuka Y., Kadota S., Phytother. Res., 15, 561-571 (2001).
6. Lee Y. T., Don M. J., Hung P. S., Shen Y. C., Lo Y. S., Chang K. W., Chen C. F., Ho L. K., Cancer Lett., 223, 19-25 (2005).
7. Xiang D., Wang D., He Y., Xie J., Zhong Z., Li Z., Xie J., Anti-Cancer Drugs, 17, 753-762 (2006).
8. Messerli S. M., Ahn M. R., Kunimasa K., Yanagihara M., Tatefuji T., Hashimoto K., Mautner V., Uto Y., Hori H., Kumazawa S., Kaji K., Ohta T., Maruta H., Phytother. Res., 23, 423-427 (2009).
9. Chen C. N., Wu C. L., Lin, J. K., Cancer Lett., 245, 218-231 (2007).
10. Chen C. N., Wu C. L., Lin, J. K., Biochem. Pharmacol., 67, 53-66 (2004).
11. Banskota A. H., Tezuka Y., Prasain J. K., Matsushige K., Saiki I., Kadota S., J. Nat. Prod., 61, 896-900 (1998).
12. Banskota A. H., Tezuka Y., Midorikawa K., Matsushige K., Kadota S., J. Nat. Prod., 63, 1277-1279 (2000).
13. Banskota A. H., Tezuka Y., Adnyana I. K., Midorikawa K., Matsushige K., Message D., Huertas A. A. G., Kadota S., J. Ethnopharmacol., 72, 239-246 (2000).
14. Usia T., Banskota A. H., Tezuka Y., Midorikawa K., Matsushige K., Kadota S., J. Nat. Prod., 65, 673-676 (2002).
15. Banskota A. H., Nagaoka T., Sumioka L. Y., Tezuka Y., Awale S., Midorikawa K., Matsushige K., Kadota S., J. Ethnopharmacol., 80, 67-73 (2002).
16. Han M. M., Banskota A. H., Tezuka Y., Midorikawa K., Matsushige K., Kadota S., J. Trad. Med., 20, 20-29 (2003).
17. Awale S., Shrestha S. P., Tezuka Y., Ueda J., Matsuchige K., Kadota S., J. Nat. Prod., 68, 858-864 (2005).
18. Li F., Awale S., TezukaY., Kadota S., Bioorg. Med. Chem., 16, 5434-5440 (2008).
19. Awale S., Li F., Onozuka H., Esumi H., Tezuka Y., Kadota S., Bioorg. Med. Chem., 16, 181-189 (2008).
20. Li F., Awale S., Zhang H., Tezuka Y., Esumi H., Kadota S., J. Nat. Prod., 72, 1283-1287 (2009).
21. Ohnishi Y., Sakamoto T., Fujii H., Kimura F., Murata J., Tazawa K., Fujimaki M., Sato Y., Kondo M., Une Y., Uchino J., Saiki I., Tumor Biol., 18, 113-122 (1997).
22. Hart I. R., Am. J. Pathol., 97, 587-600 (1979).
23. Aptekman P. M., Lewis M. R., J. Immunol., 66, 361-364 (1951).
24. Giard J. D., Aaronoson S. A., Todaro G. J., Arnstein P., Kersey J. H., Dosik H., Parks W. P., J. Natl. Cancer Inst., 51, 1417-1423 (1973).
25. Gey G. O., Coffman W. D., Cancer Res., 12, 264-265 (1952).
26. Rasheed S., Nelson-Rees W. A., Thot E. M., Arnstein P., Gardner M. B., Cancer, 33, 1027-1033 (1974).
27. Liu Y., Peterson D. A., Kimura H., Schubert D., J. Neurochem., 69, 581-593 (1997).
28. Banskota A. H., Tezuka Y., Prasain J. K., Matsushige K., Saiki I., Kadota S., J. Nat. Prod., 61, 896-900 (2005).
29. Saito K., Oku T., Ata N., Miyashiro H., Hattori M., Saiki I., Biol. Pharm. Bull., 20, 345-348 (1997).
30. Watjen W., Weber N., Lou Y. J., Wang Z. Q., Chovolou Y., Kanpkotter A., Kahl R., Proksch P., Food Chem. Toxicol., 45, 119-124 (2007).
31. Plochmann K., Korte G., Koutsilieri E., Richling E., Riederer P., Rethwilm A., Schreier P., Scheller C., Arch. Biochem. Biophys., 460, 1-9 (2007).